Form 8-K - Current report:
SEC Accession No. 0001628280-22-005394
Filing Date
2022-03-08
Accepted
2022-03-08 16:58:48
Documents
14
Period of Report
2022-03-08
Items
Item 2.02: Results of Operations and Financial Condition
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K aqst-20220308.htm   iXBRL 8-K 37210
2 EX-99.1 aqst-q421xex991.htm EX-99.1 220244
6 aqstlogo.jpg GRAPHIC 14528
  Complete submission text file 0001628280-22-005394.txt   434427

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT aqst-20220308.xsd EX-101.SCH 1899
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT aqst-20220308_lab.xml EX-101.LAB 24927
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT aqst-20220308_pre.xml EX-101.PRE 13133
8 EXTRACTED XBRL INSTANCE DOCUMENT aqst-20220308_htm.xml XML 11269
Mailing Address 30 TECHNOLOGY DRIVE WARREN NJ 07059
Business Address 30 TECHNOLOGY DRIVE WARREN NJ 07059 908-941-1900
Aquestive Therapeutics, Inc. (Filer) CIK: 0001398733 (see all company filings)

EIN.: 208623253 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-38599 | Film No.: 22722492
SIC: 2834 Pharmaceutical Preparations